Blood Pressure-Lowering Effects of Aldosterone Synthase Inhibitors-A Systematic Review.

ABSTRACT: Excess aldosterone production contributes to the development of hypertension and results in fibrosis with dysfunction of the heart, vasculature and kidneys. Consequently, new agents have been developed to reduce endogenous aldosterone synthesis. The primary objective of this systematic review is to describe the BP-lowering effects of aldosterone synthase inhibitors (ASIs) in hypertensive patients and, secondly, to describe their potential renal protective effects and possible influence on cortisol production and plasma potassium. We searched PubMed, Embase and ClinicalTrials.gov and included randomized controlled and clinical trials according to PICO using the review tool Covidence. Thirteen studies were included and all demonstrated BP reduction through ASI treatment. Among patients with

SUBMITTER: Rasmussen AA 

PROVIDER: S-EPMC12281267 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature